Immunocore Holdings plc

Immunocore Holdings plc is a biotechnology company focused on developing and commercializing immunomodulating medicines for patients with cancer, infectious diseases, and autoimmune diseases globally. Its lead approved product is KIMMTRAK, used for treating unresectable or metastatic uveal melanoma. The company also has a robust pipeline including tebentafusp in Phase 3 for advanced cutaneous melanoma and adjuvant uveal melanoma, brenetafusp in Phase 3 for first-line advanced cutaneous melanoma and Phase 1/2 for various tumors, IMC-R117C in Phase 1/2 for advanced solid tumors like colorectal cancer, and IMC-P115C in Phase 1 for PRAME-expressing tumors. Additionally, Immunocore is developing IMC-M113V for HIV and IMC-I109V for hepatitis B, both in Phase 1, and early-stage programs for type 1 diabetes and atopic dermatitis.

Immunocore Holdings plc is listed on the Nasdaq Global Select Market (NasdaqGS) under the ticker symbol IMCR. The company trades in US Dollars (USD), which is the currency used for its stock transactions and financial reporting. Being listed on a major US exchange provides Immunocore with access to a broad base of international investors and enhances its visibility in the global capital markets.

Immunocore operates in the Healthcare sector, specifically within the Biotechnology industry. As a biotechnology company, it focuses on researching, developing, and commercializing innovative therapies that harness the immune system to fight diseases. Its work primarily involves immunomodulating medicines, which are designed to modify or regulate the immune response to treat conditions such as cancer, infectious diseases, and autoimmune disorders. This places Immunocore at the forefront of immuno-oncology and immunotherapy.

Immunocore Holdings plc is headquartered in Abingdon, United Kingdom. The company was founded in 1999 and has since grown to serve a global market, with its therapies targeting patients worldwide. Its approved product KIMMTRAK is available for patients with unresectable or metastatic uveal melanoma, and its pipeline includes treatments for various cancers, HIV, hepatitis B, type 1 diabetes, and atopic dermatitis. While based in the UK, Immunocore's clinical trials and commercial activities span multiple countries, reflecting its international reach in addressing serious diseases.

Immunocore's key approved product is KIMMTRAK, a treatment for unresectable or metastatic uveal melanoma. Its pipeline includes several promising candidates: tebentafusp in Phase 3 for advanced cutaneous melanoma and adjuvant uveal melanoma; brenetafusp in Phase 3 for first-line advanced cutaneous melanoma and Phase 1/2 for various tumor types; IMC-R117C in Phase 1/2 for advanced solid tumors including colorectal cancer; and IMC-P115C in Phase 1 for PRAME-expressing tumors. For infectious diseases, the company has IMC-M113V in Phase 1 for HIV and IMC-I109V in Phase 1 for hepatitis B, both aiming for functional cures. Additionally, early-stage programs include IMC-S118AI for type 1 diabetes and IMC-U120AI for atopic dermatitis, both in pre-investigation stages.